Mavyret is a combination of direct-acting antiviral drugs that reduce the amount of HCV in the body to undetectable levels by preventing the virus from multiplying, and in most cases, curing HCV
Antiviral (Hepatitis C Virus [HCV] NS5A Inhibitor, HCV NS3/4A Protease Inhibitor, Cytochrome P450 3A Inhibitor, plus HCV NS5B Polymerase Inhibitor)
and amiodarone. Antiviral drugs. Coadministration of amiodarone with sofosbuvir alone or in combination with another HCV direct acting
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated
HCV/HIV Coinfection. The treatment of hepatitis C virus (HCV) infection is rapidly evolving. Patients with HCV/HIV coinfection treated with all-oral, direct-acting antiviral (DAA) HCV regimens can achieve sustained virologic response (HCV cure) at rates comparable to those in patients with HCV mono-infection. 1-3 This section of the guidelines focuses on hepatic safety and drug drug
Patients with HIV/HCV coinfection. HCV medications such as direct antiviral medications should be used with antiretroviral medications without
Antiviral (Hepatitis C Virus [HCV] NS5A Inhibitor, HCV NS3/4A Protease Inhibitor, Cytochrome P450 3A Inhibitor, plus HCV NS5B Polymerase Inhibitor)
Background: As direct-acting antiviral treatment for hepatitis C virus (HCV) The risk factor of having injected drugs was present in all HCV-Ab
(FDA) defines direct-acting hepatitis C virus (HCV) antivirals as drugs that interfere with antiviral drug that is approved and recommended for treatment of
Antiviral drugs are a class of medication used specifically for treating viral infections